Cargando…
Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats
Parkinson's disease (PD) is the second most common neurodegenerative disorder, and the main cause of PD is still not known. Until now, no cure for Parkinson's disease is yet in sight. Caffeic acid phenethyl ester (CAPE) is a polyphenolic component of the propolis, which can be derived from...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424247/ https://www.ncbi.nlm.nih.gov/pubmed/34512945 http://dx.doi.org/10.1155/2021/5553480 |
_version_ | 1783749636239917056 |
---|---|
author | Soner, Burak Cem Acikgoz, Eda Inan, Salim Yalcin Ayla, Sule Sahin, Ayse Saide Oktem, Gulperi |
author_facet | Soner, Burak Cem Acikgoz, Eda Inan, Salim Yalcin Ayla, Sule Sahin, Ayse Saide Oktem, Gulperi |
author_sort | Soner, Burak Cem |
collection | PubMed |
description | Parkinson's disease (PD) is the second most common neurodegenerative disorder, and the main cause of PD is still not known. Until now, no cure for Parkinson's disease is yet in sight. Caffeic acid phenethyl ester (CAPE) is a polyphenolic component of the propolis, which can be derived from honeybee hive propolis. We aimed to determine the effect of intrastriatal CAPE administration as a neuroprotective agent on 6-hydroxydopamine (6-OHDA)-induced PD model. Adult male Wistar rats weighing 280–320 g were used. The PD model was induced with unilateral intrastriatal 6-OHDA injection. Treatment groups received 20 μmol/5 μL/4 day and 80 μmol/5 μL/4 day CAPE 24 h after 6-OHDA injection. Eight days after 6-OHDA application, behavioral studies (adhesive tape removal test, open-field test, cylinder test, and apomorphine-induced asymmetric rotational behavior) were performed once more to compare the effects of CAPE on behavior tests. Striatal histological verifications, immunohistochemistry, and stereological quantitation were performed. Our results for the first time showed that, besides improving the motor performance, CAPE treatment also prevents 6-OHDA-induced loss of TH-positive neurons. From our results, CAPE may be a promising clinical agent in the treatment of PD. |
format | Online Article Text |
id | pubmed-8424247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-84242472021-09-09 Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats Soner, Burak Cem Acikgoz, Eda Inan, Salim Yalcin Ayla, Sule Sahin, Ayse Saide Oktem, Gulperi Parkinsons Dis Research Article Parkinson's disease (PD) is the second most common neurodegenerative disorder, and the main cause of PD is still not known. Until now, no cure for Parkinson's disease is yet in sight. Caffeic acid phenethyl ester (CAPE) is a polyphenolic component of the propolis, which can be derived from honeybee hive propolis. We aimed to determine the effect of intrastriatal CAPE administration as a neuroprotective agent on 6-hydroxydopamine (6-OHDA)-induced PD model. Adult male Wistar rats weighing 280–320 g were used. The PD model was induced with unilateral intrastriatal 6-OHDA injection. Treatment groups received 20 μmol/5 μL/4 day and 80 μmol/5 μL/4 day CAPE 24 h after 6-OHDA injection. Eight days after 6-OHDA application, behavioral studies (adhesive tape removal test, open-field test, cylinder test, and apomorphine-induced asymmetric rotational behavior) were performed once more to compare the effects of CAPE on behavior tests. Striatal histological verifications, immunohistochemistry, and stereological quantitation were performed. Our results for the first time showed that, besides improving the motor performance, CAPE treatment also prevents 6-OHDA-induced loss of TH-positive neurons. From our results, CAPE may be a promising clinical agent in the treatment of PD. Hindawi 2021-08-30 /pmc/articles/PMC8424247/ /pubmed/34512945 http://dx.doi.org/10.1155/2021/5553480 Text en Copyright © 2021 Burak Cem Soner et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Soner, Burak Cem Acikgoz, Eda Inan, Salim Yalcin Ayla, Sule Sahin, Ayse Saide Oktem, Gulperi Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats |
title | Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats |
title_full | Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats |
title_fullStr | Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats |
title_full_unstemmed | Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats |
title_short | Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats |
title_sort | neuroprotective effect of intrastriatal caffeic acid phenethyl ester treatment in 6-oh dopamine model of parkinson's disease in rats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424247/ https://www.ncbi.nlm.nih.gov/pubmed/34512945 http://dx.doi.org/10.1155/2021/5553480 |
work_keys_str_mv | AT sonerburakcem neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats AT acikgozeda neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats AT inansalimyalcin neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats AT aylasule neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats AT sahinaysesaide neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats AT oktemgulperi neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats |